• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: GENZYME CORPORATION(RIDGEFIELD) SYNVISC ONE; MOZ

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

GENZYME CORPORATION(RIDGEFIELD) SYNVISC ONE; MOZ Back to Search Results
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Arthritis (1723); Fall (1848); Muscle Spasm(s) (1966); Arthralgia (2355); Neck Pain (2433); No Code Available (3191)
Event Date 06/08/2015
Event Type  Injury  
Event Description
Somnolent/hard time staying awake [sleepy], excruciating pain in my legs [pain legs], excruciating pain in my shoulders [shoulder pain], severe leg spasms [spasms], left knee began giving out [unspecified disorder of knee joint], torn meniscus/a torn meniscus in the left knee/a complex tear of the meniscus in the right knee [meniscus tear], hip bursitis [hip bursitis], pseudogout [pseudogout], broken neck [neck injury], fell/had more falls [fall], neck pain [neck pain], pseudoseptic acute arthritis/systemic pseudoseptic acute arthritis/inflammation [pseudoseptic arthritis], ([device use issue], ) excruciating pain in my ankles, knees, hips [joint pain].Case narrative: case was initially submitted via sanofi legacy database and is now being re-distributed to fda at their request.This unsolicited case from united states was received on 06-apr-2018 via health authority usa-fda (reference number: mw5075286) from the health care professional.This case concerns a patient (age, gender unspecified) who received treatment with synvisc one injection and same day developed somnolent/hard time staying awake, excruciating pain in my legs, excruciating pain in my shoulders, severe leg spasms, left knee began giving out(latency: few days), torn meniscus/a torn meniscus in the left knee/a complex tear of the meniscus in the right knee, pseudoseptic acute arthritis/systemic pseudoseptic acute arthritis/inflammation, hip bursitis, pseudogout, torn tendons(latency: unk), broken neck(latency: unk), excruciating pain in my ankles, knees, hips and fell/had more falls (latency: few days).No relevant medical history, concomitant medications and concurrent condition were reported.Patient had 4-5 synvisc injections privately over 3-4 years with excellent results.On (b)(6) 2015, the patient received treatment with intra-articular synvisc one injection, once for unknown indication (dose: unknown).The same day patient developed somnolent/hard time staying awake, excruciating pain in my legs, excruciating pain in my shoulders, severe leg spasms and excruciating pain in my ankles, knees, hips.On an unknown date in (b)(6) 2015, few days after initiating treatment, patient's left knee began giving out.On an unknown date in 2015, after unknown latency, patient had fell/had more falls , torn meniscus/a torn meniscus in the left knee/a complex tear of the meniscus in the right knee and the injection went into the tissue and caused inflammation.On an unknown date, after unknown latency, patient developed pseudoseptic acute arthritis/systemic pseudoseptic acute arthritis, hip bursitis, pseudogout, torn tendons and broken neck.Corrective treatment: not reported for all the events.Outcome: unknown for all the events.Seriousness criteria: medically significant for all the events.A pharmaceutical technical complaint (ptc) was initiated and results were pending for the same.Pharmacovigilance comment: sanofi company comment dated 16-apr-2018: based on the information received, the causal relationship between the suspect product and event could not be denied.Also, lack of information regarding patient's medical history, concurrent illness, concomitant medication and lab tests leads to incomplete assessment of the case.
 
Event Description
This unsolicited case from united states was received on 06-apr-2018 via health authority usa-fda (reference number: mw5075286) from the health care professional.This case concerns a patient (age, gender unspecified) who received treatment with synvisc one injection and same day developed somnolent/hard time staying awake, "excruciating" pain in my legs, "excruciating" pain in my shoulders, severe leg spasms, left knee began giving out(latency: few days), torn meniscus/a torn meniscus in the left knee/a complex tear of the meniscus in the right knee, pseudoseptic acute arthritis/systemic pseudoseptic acute arthritis/inflammation, hip bursitis, pseudogout, torn tendons(latency: unk), broken neck(latency: unk), "excruciating" pain in my ankles, knees, hips and fell/had more falls (latency: few days).No relevant medical history, concomitant medications and concurrent condition were reported.Patient had 4-5 synvisc injections privately over 3-4 years with excellent results.On (b)(6) 2015, the patient received treatment with intra-articular synvisc one injection, once for unknown indication (dose: unknown).The same day patient developed somnolent/hard time staying awake, "excruciating" pain in my legs, "excruciating" pain in my shoulders, severe leg spasms and "excruciating" pain in my ankles, knees, hips.On an unknown date in (b)(6) 2015, few days after initiating treatment, patient's left knee began giving out.On an unknown date in 2015, after unknown latency, patient had fell/had more falls, torn meniscus/a torn meniscus in the left knee/a complex tear of the meniscus in the right knee and the injection went into the tissue and caused inflammation.On an unknown date, after unknown latency, patient developed pseudoseptic acute arthritis/systemic pseudoseptic acute arthritis, hip bursitis, pseudogout, torn tendons and broken neck.Corrective treatment: not reported for all the events outcome: unknown for all the events seriousness criteria: medically significant for all the events.A pharmaceutical technical complaint (ptc) was initiated and results were pending for the same.Pharmacovigilance comment: sanofi company comment dated 16-apr-2018: based on the information received, the causal relationship between the suspect product and event could not be denied.Also, lack of information regarding patient's medical history, concurrent illness, concomitant medication and lab tests leads to incomplete assessment of the case.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
SYNVISC ONE
Type of Device
MOZ
Manufacturer (Section D)
GENZYME CORPORATION(RIDGEFIELD)
1125 pleasantview terrace
ridgefield 07657
Manufacturer (Section G)
GENZYME CORPORATION(RIDGEFIELD)
1125 pleasantview terrace
ridgefield 07657
Manufacturer Contact
heather schiappacasse
55 corporate drive, ms 55b-220
a
bridgewater 08807
MDR Report Key7478876
MDR Text Key213409555
Report Number2246315-2018-00458
Device Sequence Number1
Product Code MOZ
Combination Product (y/n)N
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Health Professional
Reporter Occupation Other Health Care Professional
Type of Report Initial
Report Date 08/26/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received05/02/2018
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention; Other;
-
-